Scholarlink

Background <p>Dexamethasone is commonly administered perioperatively in malignant glioma craniotomies to mitigate peritumoral edema and associated mass effects. However, prolonged steroid exposure impairs survival outcomes through immunosuppression. The optimal timing for postoperative steroid withdrawal remains unclear. This study investigates the association between early postoperative corticosteroid withdrawal and outcomes following malignant glioma craniotomy.</p> Methods <p>A retrospective cohort analysis was conducted using the TriNetX database. Propensity score matching (PSM) was performed to form two balanced groups comparing patients with early steroid withdrawal (discontinuation of within 7 days postoperatively and no reinitiation within 3 months) versus late steroid withdrawal (any steroid use between 7 days and 3 months postoperatively). Primary outcomes were survival at 6 months, 1 year, and 2 years. Secondary outcomes included perioperative complications including meningitis, cerebrospinal fluid (CSF) leak, intracranial hemorrhage, venous thromboembolism, and early reoperation.</p> Results <p>A total of 34,693 patients were included in the crude cohort. After PSM, 5922 patients were included in both groups. Early withdrawal of corticosteroid was associated with improved survival (6 months: HR 0.57, <i>p</i> &lt; 0.001, 1 year: HR 0.65, <i>p</i> &lt; 0.001, 2 years: HR 0.70, <i>p</i> &lt; 0.001). Additionally, early steroid withdrawal was associated with lower incidence of meningitis (1-month: 0.4% vs. 1.3%, <i>p</i> &lt; 0.001; 6-month: 0.7% vs. 2.3%, <i>p</i> &lt; 0.001), CSF leak (1-month: 0.6% vs. 1.5%, <i>p</i> &lt; 0.001; 6-month: 0.9% vs. 2.5%, <i>p</i> &lt; 0.001), intracranial hemorrhage (1-month: 2.2% vs. 2.8%, <i>p</i> = 0.041; 6-month: 3.8% vs. 5.5%, <i>p</i> &lt; 0.001), venous thromboembolism (1-month: 2.4% vs. 4.6%, <i>p</i> &lt; 0.001; 6-month: 4.5% vs. 9.3%, <i>p</i> &lt; 0.001), and early reoperation (4.9% vs. 11.3%, <i>p</i> &lt; 0.001).</p> Conclusions <p>In patients undergoing malignant glioma craniotomy, early postoperative steroids withdrawal was associated with improved survival and lower incidence of perioperative complications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Early withdrawal of systemic corticosteroid following malignant glioma craniotomy: a real-world population-based cohort study

  • 期刊论文

  • 发表日期：

    2026年2月19日

查看全文
  • Chia-En Wong,
  • Yu-Chen Kuo,
  • Pei-Wen Chen,
  • Po-Hsuan Lee,
  • Pang-Shuo Perng,
  • Yen-Ta Huang,
  • Heng-Juei Hsu,
  • Ching-Ying Wang,
  • Jung-Shun Lee

摘要

Background

Dexamethasone is commonly administered perioperatively in malignant glioma craniotomies to mitigate peritumoral edema and associated mass effects. However, prolonged steroid exposure impairs survival outcomes through immunosuppression. The optimal timing for postoperative steroid withdrawal remains unclear. This study investigates the association between early postoperative corticosteroid withdrawal and outcomes following malignant glioma craniotomy.

Methods

A retrospective cohort analysis was conducted using the TriNetX database. Propensity score matching (PSM) was performed to form two balanced groups comparing patients with early steroid withdrawal (discontinuation of within 7 days postoperatively and no reinitiation within 3 months) versus late steroid withdrawal (any steroid use between 7 days and 3 months postoperatively). Primary outcomes were survival at 6 months, 1 year, and 2 years. Secondary outcomes included perioperative complications including meningitis, cerebrospinal fluid (CSF) leak, intracranial hemorrhage, venous thromboembolism, and early reoperation.

Results

A total of 34,693 patients were included in the crude cohort. After PSM, 5922 patients were included in both groups. Early withdrawal of corticosteroid was associated with improved survival (6 months: HR 0.57, p < 0.001, 1 year: HR 0.65, p < 0.001, 2 years: HR 0.70, p < 0.001). Additionally, early steroid withdrawal was associated with lower incidence of meningitis (1-month: 0.4% vs. 1.3%, p < 0.001; 6-month: 0.7% vs. 2.3%, p < 0.001), CSF leak (1-month: 0.6% vs. 1.5%, p < 0.001; 6-month: 0.9% vs. 2.5%, p < 0.001), intracranial hemorrhage (1-month: 2.2% vs. 2.8%, p = 0.041; 6-month: 3.8% vs. 5.5%, p < 0.001), venous thromboembolism (1-month: 2.4% vs. 4.6%, p < 0.001; 6-month: 4.5% vs. 9.3%, p < 0.001), and early reoperation (4.9% vs. 11.3%, p < 0.001).

Conclusions

In patients undergoing malignant glioma craniotomy, early postoperative steroids withdrawal was associated with improved survival and lower incidence of perioperative complications.